Cytokinetics Ownership
| CYTK Stock | USD 49.46 0.51 1.02% |
Shares in Circulation | First Issued 2003-03-31 | Previous Quarter 109.2 M | Current Value 117.7 M | Avarage Shares Outstanding 36.6 M | Quarterly Volatility 32.2 M |
Cytokinetics |
Cytokinetics Stock Ownership Analysis
About 99.0% of the company shares are held by institutions such as insurance companies. The company recorded a loss per share of 5.38. Cytokinetics had not issued any dividends in recent years. The entity had 1:6 split on the 25th of June 2013. Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company was incorporated in 1997 and is headquartered in South San Francisco, California. Cytokinetics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 253 people. For more info on Cytokinetics please contact Robert Blum at 650 624 3000 or go to https://www.cytokinetics.com.Besides selling stocks to institutional investors, Cytokinetics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Cytokinetics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Cytokinetics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Cytokinetics Quarterly Liabilities And Stockholders Equity |
|
Cytokinetics Insider Trades History
Less than 1% of Cytokinetics are currently held by insiders. Unlike Cytokinetics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Cytokinetics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Cytokinetics' insider trades
Cytokinetics Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Cytokinetics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Cytokinetics backward and forwards among themselves. Cytokinetics' institutional investor refers to the entity that pools money to purchase Cytokinetics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Boxer Capital Llc | 2024-09-30 | 2.1 M | Pictet Asset Manangement Sa | 2024-09-30 | 2.1 M | Armistice Capital, Llc | 2024-09-30 | 1.9 M | Marshall Wace Asset Management Ltd | 2024-09-30 | 1.9 M | Partner Fund Management Lp | 2024-09-30 | 1.8 M | Alliancebernstein L.p. | 2024-09-30 | 1.7 M | Vestal Point Capital Lp | 2024-09-30 | 1.5 M | Northern Trust Corp | 2024-09-30 | 1.3 M | Charles Schwab Investment Management Inc | 2024-09-30 | 1.3 M | Blackrock Inc | 2024-09-30 | 15.3 M | Fmr Inc | 2024-09-30 | 12.1 M |
Cytokinetics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Cytokinetics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Cytokinetics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Cytokinetics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Cytokinetics Outstanding Bonds
Cytokinetics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Cytokinetics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Cytokinetics bonds can be classified according to their maturity, which is the date when Cytokinetics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Volcan Compania Minera Corp BondUSP98047AC08 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View |
Cytokinetics Corporate Filings
F4 | 21st of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 8th of January 2025 Other Reports | ViewVerify | |
8K | 16th of December 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 14th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cytokinetics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Cytokinetics Stock please use our How to buy in Cytokinetics Stock guide.You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytokinetics. If investors know Cytokinetics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytokinetics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (5.38) | Revenue Per Share | Quarterly Revenue Growth 0.225 | Return On Assets | Return On Equity |
The market value of Cytokinetics is measured differently than its book value, which is the value of Cytokinetics that is recorded on the company's balance sheet. Investors also form their own opinion of Cytokinetics' value that differs from its market value or its book value, called intrinsic value, which is Cytokinetics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytokinetics' market value can be influenced by many factors that don't directly affect Cytokinetics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cytokinetics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytokinetics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytokinetics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.